Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See why NVO stock is a buy.

Novo Nordisk is gearing up for its largest-ever corporate summer party, inviting employees to the Animal Fairgrounds in Roskilde on August 22. The pharmaceutical company expects more than 20,000 ...

The price of parking has skyrocketed. Several municipalities have expanded payment zones, raised fees, and residents must pay more for licenses to have their cars parked near their homes, DR reports.

This month, the Danish prime minister Mette Frederiksen takes up her presidency of the EU – and the timing could not be more ...

Novo Nordisk dished out an up-front payment of $200 million (not to mention potential milestone payments of up to $1.8 billion) to acquire UBT251, a triple agonist -- that is, a medicine that ...

Novo Nordisk (NVO 1.20%) stock, maker of the blockbuster GLP-1 agonist weight-loss drugs Ozempic and Wegovy, jumped a lucky 7% through 12:20 p.m. ET Tuesday after London's Financial Times reported ...

Leading Global Pharma Joins Danish Enterprises, Startups and Public Health Systems Using AI Factories to Improve Drug Discovery and Healthcare Novo Nordisk / DCAI NVIDIA is collaborating with Novo ...

Novo Nordisk's U.S.-listed shares have lost nearly half their value in the last 12 months as sales growth for its landmark weight loss drugs Ozempic and Wegovy have started to slow.